Trial Profile

Phase II Study Evaluating the Combination of Cetuximab With Afatinib as First-line Treatment for Patients With EGFR Mutated Non Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afatinib (Primary) ; Cetuximab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions
Acronyms ACE; ACE-Lung

Most Recent Events

24 May 2021 Results (n=117) assessing efficacy and toxicity of afatinib+cetuximab versus afatinib alone, in first-line treatment of advanced EGFR-mutant non-small-cell lung cancer, published in the Clinical Cancer Research.
04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
11 Feb 2019 Planned End Date changed from 1 Jan 2020 to 1 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com